Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
Adlai Nortye announced a late-breaking oral presentation of AN4035 program data at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 19. The presentation will cover translational and EGFR-combination data for AN4035, a first-in-class CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, now in a global Phase I trial across Australia, the U.S., and China.
Key figures
- Drug Name
- AN4035
- Phase Of Trial
- Phase I
- Conference
- 38th EORTC-NCI-AACR (ENA) Symposium
- Presentation date
- 2026-11-19
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.